In a significant development for global public health, Hyderabad-based Biological E. Limited (BE) has announced the World Health Organization (WHO) pre-qualification of its Novel Oral Polio Vaccine type 2 (nOPV2). This milestone marks the 10th vaccine from BE to receive WHO pre-qualification, underscoring the company’s pivotal role in the ongoing fight against polio, a press-note released on July 30, stated.
Enhanced Vaccine Efficacy
nOPV2, a next-generation live, attenuated oral vaccine, is engineered to mitigate the risks associated with circulating vaccine-derived Poliovirus type 2 (cVDPV2) outbreaks, particularly in low-immunity areas. Unlike its predecessor, the Sabin poliovirus type 2 (mOPV2) vaccine, nOPV2 boasts enhanced genetic stability, significantly reducing the likelihood of the vaccine virus reverting to a virulent form and sparking new outbreaks.
Clinical Trials & Real-World Impact
The introduction of nOPV2 comes at a critical time, with cVDPV2 continuing to pose a severe health threat in several regions. Rigorous clinical trials, extensively documented in The Lancet over a five-year period from 2019 to 2024, have validated the vaccine’s safety and efficacy. Real-world applications in affected regions have demonstrated a substantial reduction in cVDPV2 incidents, contributing to the broader global effort to protect communities from polio.
Global Production & Collaboration
Biological E.’s substantial production capabilities, bolstered by a strategic grant from the Bill and Melinda Gates Foundation, have positioned the company as a major contributor to the global vaccine supply. In collaboration with Indonesia’s PT BioFarma (PTB)—the first manufacturer to receive WHO pre-qualification for nOPV2 in January 2024—BE has adopted advanced technology to facilitate the production of over 500 million doses annually, approved for export by Indian regulatory authorities.
Executive Insight
Mahima Datla, Managing Director at Biological E., expressed her satisfaction with the WHO’s recognition and highlighted the broader implications of this achievement.
“Receiving WHO pre-qualification for nOPV2 is not just a scientific achievement; it is a hopeful milestone for millions worldwide. Our commitment extends beyond manufacturing a vaccine. We are dedicated to ensuring that no child must endure the devastating effects of polio,” she said.
Datla also acknowledged the collaborative efforts with PT BioFarma and the Gates Foundation’s pivotal support: “Our partnership with PTB and the backing of the Gates Foundation are invaluable to our operations. This collaboration is key to our mission of promoting global health equity and advancing towards a polio-free future.”
A Milestone in Polio Eradication
The successful deployment of over 1 billion doses of nOPV2 in outbreak-prone areas stands as a testament to the global health community’s resolve to eradicate polio and safeguard future generations from this debilitating disease.
–Raja Aditya
